Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
RADELUMIN 2000 MBq/ml solution injectable, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 2000 MBq/ml Injektionslösung, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 2000 MBq/mL solución inyectable, Radelumin 2000 MBq/ml oplossing voor injectie, RADELUMIN 2000 MBq/ml solution injectable, Radelumin 1300 MBq/ml Injektionslösung, Radelumin 1300 MBq/ml oplossing voor injectie, RADELUMIN 2000 MBq/ml solution injectable, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 1300 MBq/mL solución inyect
Advanced Accelerator Applications
Prostate Cancer
1 trial -
SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion
Advanced Accelerator Applications
Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs
1 trial -
Diagnóstico prick Dermatophagoides pteronyssinus, Diagnóstico prick Dermatophagoides pteronyssinus, Diagnóstico prick Dermatophagoides pteronyssinus, Diagnóstico prick control positivo, Diagnóstico prick control negativo, Diagnóstico prick Dermatophagoides pteronyssinus
Advanced Accelerator Applications
Allergies
1 trial -
Diagnóstico prick Lepidoglyphus destructor, Diagnóstico prick Lepidoglyphus destructor, Diagnóstico prick Lepidoglyphus destructor, Diagnóstico prick control negativo, Diagnóstico prick control positivo
Advanced Accelerator Applications
Allergies
1 trial -
LysaKare 25 g/25 g solution for infusion, Lutathera 370 MBq/mL solution for infusion
Advanced Accelerator Applications
somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas
1 trial -
Vacuna Dermatophagoides mezcla Placebo, Vacuna Dermatophagoides mezcla 3000 TBU/ml, Test de provocación nasal, Vacuna Dermatophagoides mezcla 6000 TBU/ml, Vacuna Dermatophagoides mezcla 1000 TBU/ml
Advanced Accelerator Applications
Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy
1 trial -
[177Lu]-NeoB solution for infusion, AAA503
Advanced Accelerator Applications
Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake.
1 trial -
First-In-Human study evaluating the Safety of administration of ABD-3001 to Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes
Advanced Accelerator Applications
Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes, Ineligible for Intensiveor New Generation Targeted Therapy
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources